Orforglipron

Foundayo · Eli Lilly. The first small-molecule GLP-1 pill: no food, water or timing rules. The trade-off is the least weight loss and the highest quit rate among approved options.

Average weight loss

12.4%

Stopped for side effects

10.3%

Trial length

72 wk

Ranking score

3.4

ATTAIN-1 results

Phase 3 · 72 weeks · 36 mg daily (sold as 17.2 mg tablet)
Adults with obesity, no diabetes (n=3,127)

Weight loss

12.4%

Nausea

33.7%

Vomiting

24.0%

Diarrhea

23.1%

Constipation

25.4%

Quit due to side effects

10.3%

n/r = not reported. Counting everyone who started, weight loss was 11.2%. Placebo group: 0.9%.

Worth knowing

Small molecule, so it survives digestion and is cheaper to manufacture at scale.

3.4

GLP-1 Performance Index

Rank 6 of 6 ranked drugs

Stomach = (33.7 + 24.0 + 23.1 + 25.4) ÷ 4 = 26.6 Burden = 26.6 + 1 × 10.3 = 36.9 Index = 12.4 ÷ 36.9 × 10 = 3.36

At a glance

Company: Eli Lilly
Targets: GLP-1
Molecule: Small molecule
Dosing: Oral, daily
Status: FDA approved (Apr 1, 2026)

Compare with another drug

Sources

History

Apr 1, 2026
FDA approves Foundayo (orforglipron), the first small-molecule GLP-1 pill.